Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (29)
Chen-Ju Feng, Chin-Hui Wu, Chin-Hsiung Lin, Ming-Chen Yuan, Shen-Hao Lee, David YC Huang, Jo-Yu Lin, Ying-Fang Chen & Shih-Ming Hsu. (2023) The evaluation of an on-site monitoring program for activity meter quality assurance with exemption-level sources. Journal of Radiological Protection 43:2, pages 021508.
Crossref
Crossref
Anca M. Avram. 2023. Integrated Diagnostics and Theranostics of Thyroid Diseases. Integrated Diagnostics and Theranostics of Thyroid Diseases
111
127
.
Ji Young Lee, Hee-Sung Song & Young Hwan Kim. (2022) Effect of therapeutic radioiodine activity on ablation response in differentiated thyroid cancer patients with cut-off serum thyroglobulin levels after 2 weeks of thyroid hormone withdrawal: a retrospective study. Journal of Medicine and Life Science 19:3, pages 95-102.
Crossref
Crossref
Friederike Eilsberger & Michael C. Kreissl. 2022. Nuclear Medicine and Molecular Imaging. Nuclear Medicine and Molecular Imaging
56
61
.
Friederike Eilsberger, Gerrit Ahlers & Markus Luster. 2022. Nuclear Medicine and Molecular Imaging. Nuclear Medicine and Molecular Imaging
77
86
.
George Barberio Coura-Filho, Mayara Torres Silva de Oliveira & Ana Luiza Morais de CamposGeorge Barberio Coura-Filho, Mayara Torres Silva de Oliveira & Ana Luiza Morais de Campos. 2022. Nuclear Medicine in Endocrine Disorders. Nuclear Medicine in Endocrine Disorders
171
184
.
Danielle L. James, Éanna J. Ryan, Matthew G. Davey, Alanna Jane Quinn, David P. Heath, Stephen James Garry, Michael R. Boland, Orla Young, Aoife J. Lowery & Michael J. Kerin. (2021) Radioiodine Remnant Ablation for Differentiated Thyroid Cancer. JAMA Otolaryngology–Head & Neck Surgery 147:6, pages 544.
Crossref
Crossref
I. Vardarli, F. Weidemann, M. Aboukoura, K. Herrmann, I. Binse & R. Görges. (2020) Longer-term recurrence rate after low versus high dose radioiodine ablation for differentiated thyroid Cancer in low and intermediate risk patients: a meta-analysis. BMC Cancer 20:1.
Crossref
Crossref
Pablo Mínguez, Emilia Rodeño, José Genollá, Maite Domínguez, Amaia Expósito & Katarina Sjögreen Gleisner. (2019) Analysis of activity uptake, effective half-life and time-integrated activity for low- and high-risk papillary thyroid cancer patients treated with 1.11 GBq and 3.7 GBq of 131I-NaI respectively. Physica Medica 65, pages 143-149.
Crossref
Crossref
Lan Wei, Lin Bai, Lina Zhao, Tianyu Yu, Qingjie Ma & Bin Ji. (2019) High-Dose RAI Therapy Justified by Pathological N1a Disease Revealed by Prophylactic Central Neck Dissection for cN0 Papillary Thyroid Cancer Patients: Is it Superior to Low-Dose RAI Therapy?. World Journal of Surgery 43:5, pages 1256-1263.
Crossref
Crossref
Farahnaz Waissi, Jakob W. Kist, Lutske Lodewijk, Ardine G. de Wit, Jos A. van der Hage, Thijs van Dalen, Bart de Keizer, Gerlof D. Valk, Inne H. M. Borel Rinkes & Menno R. Vriens. (2019) Fast-track Radioiodine Ablation Therapy After Thyroidectomy Reduces Sick Leave in Patients With Differentiated Thyroid Cancer (FASTHYNA Trial). Clinical Nuclear Medicine 44:4, pages 272-275.
Crossref
Crossref
Chae Moon Hong & Byeong-Cheol Ahn. (2018) Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer. Nuclear Medicine and Molecular Imaging 52:4, pages 247-253.
Crossref
Crossref
Atena Aghaei, Narjess Ayati, Susan Shafiei, Bita Abbasi & S. Rasoul Zakavi. (2017) Comparison of treatment efficacy 1 and 2 years after thyroid remnant ablation with 1110 versus 5550 MBq of iodine-131 in patients with intermediate-risk differentiated thyroid cancer. Nuclear Medicine Communications 38:11, pages 927-931.
Crossref
Crossref
Chen Wang, Teng Zhao, Hui Li, Wen Gao & Yansong Lin. (2017) Low activity versus high activity. Nuclear Medicine Communications 38:5, pages 366-371.
Crossref
Crossref
Zhaowei Meng & Xinghua Song. (2016) Reply to. Clinical Nuclear Medicine 41:8, pages 675.
Crossref
Crossref
Seyed Rasoul Zakavi. (2016) Meta-analysis on Successful Ablation After Low- Versus High-Dose Radioiodine Therapy in Patients With Differentiated Thyroid Carcinoma. Clinical Nuclear Medicine 41:8, pages 674.
Crossref
Crossref
Marin Prpic, Ivan Kruljac, Davor Kust, Lora S. Kirigin, Tomislav Jukic, Nina Dabelic, Ante Bolanca & Zvonko Kusic. (2016) Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma. Endocrine 52:3, pages 602-608.
Crossref
Crossref
Sanjana Ballal, Ramya Soundararajan, Aayushi Garg, Saurav Chopra & Chandrasekhar Bal. (2015) Intermediate‐risk differentiated thyroid carcinoma patients who were surgically ablated do not need adjuvant radioiodine therapy: long‐term outcome study. Clinical Endocrinology 84:3, pages 408-416.
Crossref
Crossref
Bryan R. HaugenErik K. AlexanderKeith C. BibleGerard M. DohertySusan J. MandelYuri E. NikiforovFurio PaciniGregory W. RandolphAnna M. SawkaMartin SchlumbergerKathryn G. SchuffSteven I. ShermanJulie Ann SosaDavid L. StewardR. Michael TuttleLeonard Wartofsky. (2016) 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26:1, pages 1-133.
Crossref
Crossref
Xinghua Song, Zhaowei Meng, Qiang Jia, Linlin Zhang, Ke Xu, Jian Tan, Guizhi Zhang, Wei Zheng, Xue Li & Jianping Zhang. (2015) Different Radioiodine Dose for Remnant Thyroid Ablation in Patients With Differentiated Thyroid Cancer. Clinical Nuclear Medicine 40:10, pages 774-779.
Crossref
Crossref
Chandrasekhar Bal, Sanjana Ballal, Ramya Soundararajan, Saurav Chopra & Aayushi Garg. (2015) Radioiodine remnant ablation in low‐risk differentiated thyroid cancer patients who had R0 dissection is an over treatment. Cancer Medicine 4:7, pages 1031-1038.
Crossref
Crossref
A Miranti, A Giostra, E Richetta, E Gino, R E Pellerito & M Stasi. (2015) Comparison of mathematical models for red marrow and blood absorbed dose estimation in the radioiodine treatment of advanced differentiated thyroid carcinoma. Physics in Medicine and Biology 60:3, pages 1141-1157.
Crossref
Crossref
Ju Won Seok. (2015) ATA Guideline in a View Point of Nuclear Medicine. International Journal of Thyroidology 8:2, pages 129.
Crossref
Crossref
Kyoung Sook Won. (2015) Low Dose versus High Dose Radioiodine Therapy. Journal of Korean Thyroid Association 8:1, pages 14.
Crossref
Crossref
Ming-Kai Chen & David W. Cheng. (2015) What is the role of dosimetry in patients with advanced thyroid cancer?. Current Opinion in Oncology 27:1, pages 33-37.
Crossref
Crossref
Juan J. D?ez, Enrique Grande & Pedro Iglesias. (2015) Ablaci?n posquir?rgica con radioyodo en pacientes con carcinoma diferenciado de tiroides de bajo riesgo. Medicina Cl?nica 144:1, pages 35-41.
Crossref
Crossref
Juan J. Díez, Enrique Grande & Pedro Iglesias. (2015) Postoperative radioiodine ablation in patients with low risk differentiated thyroid carcinoma. Medicina Clínica (English Edition) 144:1, pages 35-41.
Crossref
Crossref
Armaghan Fard-Esfahani, Alireza Emami-Ardekani, Babak Fallahi, Pezhman Fard-Esfahani, Davood Beiki, Arman Hassanzadeh-Rad & Mohammad Eftekhari. (2014) Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nuclear Medicine Communications 35:8, pages 808-817.
Crossref
Crossref
Jian Tu, Siwen Wang, Zijun Huo, Ying Lin, Xiaoxi Li & Shenming Wang. (2014) Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: A meta-analysis. Radiotherapy and Oncology 110:1, pages 25-30.
Crossref
Crossref